Georgia
Provider Communications
Anthem Blue Cross and Blue Shield clinical criteria updates for specialty pharmacy are available
Access the clinical criteria document information.
The Anthem Blue Cross and Blue Shield (Anthem) prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Drugs used for the treatment of oncology will be managed by AIM Specialty Health® (AIM) (AIM), a separate company.
ING-CC-0012 |
Brineura (cerliponase alfa) |
ING-CC-0021 |
Fabrazyme (agalsidase beta) |
ING-CC-0099 |
Abraxane (paclitaxel, protein bound) |
ING-CC-0100 |
Istodax (romidepsin) |
ING-CC-0125 |
Opdivo (nivolumab) |
ING-CC-0128 |
Tecentriq (atezolizumab) |
Featured In:
December 2021 Anthem Provider News - Georgia